Trajenta - wani sabon rukuni na magungunan maganin cututtukan fata

A shekara ta bakwai, wani magani mai ban mamaki don lura da ciwon sukari ya bayyana a kasuwa, wanda amfani da shi baya cutar da cututtukan cututtukan zuciya, kodan da hanta, in ji masu ciwon sukari. "Trazhenta", wanda ya danganta da katangar enzyme dipeptidyl peptidase-4 linagliptin, yana nufin wakilai na munafukai. Tasirin magungunan ƙwayar cuta yana nufin rage haɗarin glucagon abu na hormonal, tare da haɓaka samar da insulin. Wannan rukuni na kwayoyi a halin yanzu an gane shi a matsayin ɗayan mafi alƙawarin don sarrafa wata cuta mai haɗari - nau'in ciwon sukari na biyu.

Menene ciwon sukari?

Wannan hanya ce ta tsarin endocrine, wanda sakamakon yawan glucose a cikin jinin mutum ya karu, tunda jiki ya rasa ikon shan insulin. Sakamakon wannan cututtukan suna da mummunar matsala - tafiyar matakai na rayuwa sun lalace, tasoshin, gabobin jiki da tsarin. Ofayan mafi haɗari da rashin ƙarfi shine ciwon sukari na nau'in na biyu. Wannan cuta ana kiranta babbar barazana ga bil'adama.

Daga cikin abin da ke haifar da mace-mace a cikin shekaru 20 da suka gabata, ya zo na farko. Babban abin da ke haifar da ci gaban cutar ana daukar shi a matsayin gazawar tsarin garkuwar jiki. Magungunan rigakafi an samar da su a cikin jiki waɗanda ke da lahani a cikin ƙwayoyin ƙwayar ƙwayar cuta. Sakamakon haka, glucose a cikin adadi mai yawa yana gudana cikin jini, yana da mummunan tasiri akan gabobin da tsarin sa. Sakamakon rashin daidaituwa, jikin yana amfani da kitsen a matsayin tushen makamashi, wanda ke haifar da karuwar halittar ketone, abubuwan guba ne. A sakamakon wannan, duk nau'ikan hanyoyin haɓaka da ke faruwa a cikin jiki suna rushewa.

Sabili da haka, yana da mahimmanci musamman lokacin da ake neman ciwo don zaɓin maganin da ya dace da kuma amfani da magunguna masu ƙima, alal misali, “Trazhentu”, sake duba likitoci da marasa lafiya game da abin da za'a iya samu a ƙasa. Hadarin ciwon sukari shine cewa na dogon lokaci bazai iya ba da bayyananniyar asibiti ba, kuma ana gano abubuwan da ke tattare da ƙimar sukari kwatsam ta hanyar bincike na gaba na gaba.

Sakamakon ciwon sukari

Masana kimiyya a duniya suna ci gaba da gudanar da bincike da nufin gano sababbin dabaru don ƙirƙirar magani wanda zai iya kayar da mummunan cutar. A cikin 2012, an yi rajistar magani na musamman a cikin ƙasarmu, wanda kusan ba sa haifar da sakamako masu illa sannan kuma haƙuri yana da haƙuri sosai. Bugu da ƙari, an yarda da shi don karɓan mutane da keɓaɓɓen renal da hepatic insufficiency - kamar yadda yake a rubuce a cikin bita na "Trazhent".

Babban haɗari shine rikice-rikice na ciwon sukari:

• rage a cikin ganuwa acuity har zuwa cikakken asara,
• gazawar aikin kodan,
• na jijiyoyin zuciya da cututtukan zuciya - cututtukan zuciya na zuciya, atherosclerosis, cututtukan zuciya na zuciya,
• ƙafafun ƙafa - purulent-necrotic tafiyar matakai, rauni na raunuka,
• bayyanar ulcers a kan dermis,
• fungal fata raunuka,
• neuropathy, wanda ke bayyana ta hanyar raɗaɗi, bawo da raguwa a cikin jijiyar fata,
• coma
• keta ayyukan ƙananan hanyoyin.

"Trazhenta": bayanin, abun da ke ciki

Ana samar da magani a cikin nau'in sashi kwamfutar hannu. Allunan zagaye na biconvex allunan da aka yanke suna da farin harsashi. A gefe ɗaya akwai alamar mai ƙira, wanda aka gabatar a cikin hanyar zane, a ɗayan - zane mai fasalin D5.

Abunda yake aiki shine linagliptin, saboda babban tasirinsa don kashi ɗaya, milligram biyar ya isa. Wannan bangaren, yana haɓaka samar da insulin, yana rage haɗarin glucagon. Tasirin yana faruwa na tsawon minti dari da ashirin bayan gudanarwa - bayan wannan lokacin ne ake lura da iyakar karfin sa a cikin jini. Wadanda suka kware wajan samar da allunan:

• magnesium stearate,
• pregelatinized da masara sitaci,
• mannitol mai diuretic ne,
• copovidone shine mai narkewa.

Shell ɗin ya ƙunshi hypromellose, talc, fenti ja (baƙin ƙarfe), macrogol, titanium dioxide.

Siffofin magani

A cewar likitocin, "Trazhenta" a cikin aikin asibiti ya tabbatar da ingancinsa a cikin lura da nau'in na biyu na cututtukan mellitus a cikin ƙasashe hamsin na duniya, ciki har da Rasha. An gudanar da bincike a cikin kasashe ashirin da biyu inda dubunnan marasa lafiya da ke dauke da nau'in ciwon sukari na biyu suka shiga cikin gwada maganin.

Saboda gaskiyar cewa maganin an cire shi daga jikin mutum ta hanyar hanji, kuma ba ta hanyar kodan ba, tare da lalacewa a aikinsu, ba a buƙatar daidaita sashi ba. Wannan shine ɗayan manyan bambance-bambance tsakanin Trazenti da sauran jami'ai masu maganin cututtukan fata. Amfani mai zuwa kamar haka: mara lafiya ba shi da hypoglycemia lokacin shan allunan, duka a hade tare da Metformin, kuma tare da monotherapy.

Game da masana'antun magungunan

Samun kwamfutar hannu na Trazhenta, sake dubawa wanda ake samun su kyauta, kamfanonin kamfanoni biyu ne ke aiwatar da su.

1. “Eli Lilly” - tsawon shekaru 85 yana daya daga cikin shugabannin duniya a fagen yanke shawara mai inganci da nufin tallafawa marasa lafiya da masu dauke da cutar sankarau. Kamfanin yana haɓaka kewayonsa koyaushe ta amfani da sabon binciken.
2. “Beringer Ingelheim” - ke jagorantar tarihinta tun daga shekarar 1885. Yana tsunduma cikin bincike, ci gaba, samarwa, har da siyar da magunguna. Wannan kamfani yana ɗaya daga cikin shugabannin duniya ashirin a fagen magunguna.

A farkon shekarar 2011, dukkan kamfanonin sun sanya hannu kan wata yarjejeniya kan hadin gwiwa a fannin cutar sankara, wanda ya sami ci gaba mai yawa a fannin magance cutar ta rashin lafiya. Dalilin ma'amala ita ce yin nazarin sabon haɗuwa da abubuwa masu guɓa huɗu waɗanda wani ɓangare ne na magungunan da aka tsara don kawar da alamun cutar.

Alamu don amfani

Dangane da sake dubawa da umarni don amfani, "Trazhenta" an bada shawarar don amfani da shi don maganin nau'in mellitus na biyu na biyu tare da monotherapy kuma tare da haɗin gwiwa tare da sauran wakilai masu amfani da ƙwaƙwalwar ƙwaƙwalwar, har ma da shirye-shiryen insulin. A farkon lamari, an wajabta shi:

• contraindications don shan Metformin ko lalacewar koda,
• rashin isasshen kulawar glycemic akan asalin ilimin ilimin jiki da abinci na musamman.

Tare da rashin ingancin monotherapy tare da magunguna masu zuwa, tare da taimakon abinci da motsa jiki, ana nuna kulawa mai rikitarwa.

1. Tare da abubuwan da suka samo asali na sulfonylurea, Metformin, thiazolidinedione.
2. Tare da insulin ko Metformin, pioglitazone, sulfonylureas da insulin.
3. Tare da kayan aikin Metformin da sulfonylurea.

Contraindications

Dangane da sake dubawa da umarnin, “Trazhent” an hana shi shan yayin da jariri yake jira, da kuma lokacin ciyar da na halitta. A cikin binciken kwaskwarima, an gano cewa abu mai aiki (linagliptin) da metabolites dinsa sun shiga cikin madarar nono. Don haka, ba shi yiwuwa a fitar da mummunan sakamako ga tayin da crumbs waɗanda ke kan shayarwa. Idan ba zai yiwu a soke magungunan ba kuma su maye gurbinsa da wani makamancin haka, likitocin sun dage kan sauyawa daga dabi'a zuwa ciyar da ta mutum.

Amfani da Allunan yana contraindicated a cikin wadannan yanayi:

• shekaru zuwa goma sha takwas,
• mai ciwon sukari ketoacidosis,
• nau'in ciwon sukari guda 1
• rashin haƙuri a cikin abubuwan da ke cikin "Trazenti".

A cikin nazarin likitoci, da kuma cikin umarnin amfani da wannan magani, akwai bayanan da yakamata a yi amfani dashi tare da taka tsantsan ga mutane sama da shekara tamanin yayin ɗaukar shi tare da insulin da (ko) kwayoyi na tushen sulfonylurea. Ba a gudanar da bincike game da tasirin kwayoyi kan ikon tuki da abubuwan hawa ba. Koyaya, saboda yiwuwar faruwar cututtukan jini, musamman lokacin karɓar magani hade, yakamata a yi taka tsantsan. Idan an kamu da cutar ciwon huhu, ya kamata a dakatar da maganin. A wannan yanayin, likita zai zabi wani magani daban.

Umarni na musamman

Yana da mahimmanci a tuna cewa don kula da ketoacidosis na nau'in 1 ciwon sukari mellitus, Trazenti ya haramta. A cikin sake duba masu ciwon sukari, irin wannan gargaɗin ya zama ruwan dare gama gari. Bugu da kari, an lura cewa hadarin cututtukan cututtukan cututtukan zuciya baya karuwa. Mutane daban-daban tare da matsala na hanta da kodan na iya amintar da maganin a cikin kashi na yau da kullun, ba a buƙatar daidaitawarsa.

A cikin rukunin shekaru daga saba'in zuwa shekaru tamanin, yin amfani da linagliptin ya nuna kyakkyawan sakamako. An lura da raguwa mai girma:

• darshan hemoglobin,
• Matakan jini na jini na plasma akan komai a ciki.

Shan magungunan ta hanyar mutanen da suka tsallake alamar shekaru tamanin ya kamata a aiwatar da su tare da taka tsantsan, tunda ƙwarewar asibiti tare da wannan rukunin yana da iyakancewa.

Haɓakar haɗarin hypoglycemia yana da ƙarancin lokacin ɗaukar ɗayan "Trazenta" guda ɗaya. Nazarin haƙuri kuma ya tabbatar da wannan gaskiyar. Bugu da kari, a cikin bayanan su, sun lura cewa a hade tare da wasu magunguna don ciwon sukari, ci gaban glycemia ne sakaci. A cikin waɗannan halayen, idan ya cancanta, likita zai iya rage kashi na insulin ko abubuwan samo asali na sulfonylurea. Amincewa da "Trazhenty" baya kara hadarin bugun zuciya ko bugun jini, wanda yana da mahimmanci yayin shan shi tun tsufa.

M halayen

Yawancin magunguna da aka yi amfani da su don magance cututtukan sukari na mellitus na iya haifar da yanayin pathologies wanda matakan glucose a cikin jini ya ragu sosai, wanda ke haifar da haɗari mai mahimmanci ga mutum. "Trazhenta", a cikin bita-bita wanda aka ce ɗaukar shi ba ya haifar da hypoglycemia, togiya ce ga dokar. Wannan ana ɗaukarsa muhimmiyar fa'ida a kan sauran azuzuwan na hypoglycemic jamiái. Daga cikin halayen da ba za su iya faruwa ba yayin lokacin jiyya "Trazentoy", masu zuwa:

• maganin cututtukan farji
• tari yayi daidai
• nasopharyngitis,
• yawan tashin hankali
• hauhawar amylase plasma,
• kurji
• da sauransu.

Game da yawan abin sama da ya kamata, ana nuna matakan yau da kullun don cire wani magani mara amfani daga narkewa tare da maganin alamomin.

"Trazhenta": sake dubawa game da masu ciwon sukari da masu ilimin likita

An tabbatar da tasirin maganin sosai sau da yawa ta hanyar aikin likita da karatun ƙasa. Endocrinologists a cikin maganganun su sun ba da shawarar yin amfani da shi a hade hade ko azaman magani na farko-farko. Idan mutum yana da hali na hypoglycemia, wanda ke haifar da rashin abinci mai gina jiki da kuma aiki na jiki, yana da kyau a sanya “Trazent” a maimakon abubuwan da ake amfani da shi na sulfonylurea. Ba koyaushe zai yiwu a kimanta tasirin maganin ba idan an sha shi a hade, amma a gaba ɗaya sakamakon yana da kyau, wanda kuma masu haƙuri ke lura da shi. Akwai sake dubawa game da miyagun ƙwayoyi "Trazhenta" lokacin da aka ba da shawarar don kiba da juriya insulin.

Amfanin waɗannan magungunan maganin cututtukan ƙwayar cuta shine cewa basu bayar da tasu gudunmawa ba don karɓar nauyi, ba sa ɓarkewar haɓakar haɓakar jini, sannan kuma kar ku ƙara matsalolin koda. Trazhenta ya karu da aminci, wanda yake mahimmanci ga masu ciwon sukari. Sabili da haka, akwai adadin masu duba na kwarai game da wannan kayan aikin. Daga cikin ministocin lura da babban kudin da rashin yarda mutum.

Analog kwayoyi "Trazhenty"

Abubuwan sake dubawar da likitocin da ke shan wannan magungunan suka kasance mafi inganci Koyaya, ga wasu daidaikun mutane, saboda yawan zafin rai ko rashin haƙuri, likitoci sun ba da shawarar irin waɗannan magunguna. Wadannan sun hada da:

• "Sitagliptin", "Januvia" - marasa lafiya suna ɗaukar wannan magani azaman ƙari ga motsa jiki, abinci, don inganta ikon kula da glycemic state, ban da haka, an yi amfani da miyagun ƙwayoyi a haɗuwa da jiyya,
• "Alogliptin", "Vipidia" - galibi ana ba da shawarar wannan maganin idan babu tasirin abinci mai gina jiki, aikin jiki da monotherapy,
• "Saksagliptin" - ana samarwa a ƙarƙashin sunan kasuwanci "Ongliza" don magance nau'in na biyu na ciwon sukari, ana amfani dashi a cikin monotherapy kuma tare da sauran magungunan kwamfutar hannu da inulin.

Zaɓin analog ne kawai ta hanyar kula da endocrinologist, an hana canjin magani mai cin gashin kai.

Marasa lafiya tare da gazawar koda

"Madalla da ingantacciyar magunguna" - irin waɗannan kalmomin yawanci fara rave game da "Trazhent". Babban damuwa yayin shan magungunan maganin cututtukan ƙwaƙwalwar ƙwayar cuta koyaushe mutane sun dandana shi da raunin ƙwayoyin cuta, musamman waɗanda ke fama da cutar sankara. Tare da shigowar wannan magani a cikin cibiyar sadarwar kantin magani, marasa lafiya da ke fama da cututtukan koda sun yaba da shi, duk da babban farashin.

Saboda ƙwararren aikin magani na musamman, an rage darajar glucose sosai yayin ɗaukar maganin sau ɗaya kawai a rana a matakin warkewa na milligrams biyar. Kuma bashi da mahimmanci lokacin ɗaukar allunan. Magungunan yana cikin hanzari bayan an shiga cikin narkewa, ana lura da mafi girman hankali bayan sa'a daya da rabi ko awa biyu bayan gudanarwa. An cire shi cikin feces, wato, kodan da hanta basa shiga cikin wannan aikin.

Kammalawa

Dangane da sake duba masu ciwon sukari, ana iya ɗaukar Trazhent a kowane lokaci da ya dace, ba tare da la'akari da abinci mai gina jiki ba kuma sau ɗaya kawai a rana, wanda ake ɗauka babbar ƙari. Abinda ya kamata a tuna: ba za ku iya ɗaukar kashi biyu cikin kwana ɗaya ba. A haɗuwa da jiyya, ƙwayar "Trazhenty" ba ta canzawa. Bugu da kari, ba a buƙatar gyaransa ba idan akwai matsala tare da kodan. Allunan suna jure haƙuri sosai, halayen da ba a saba gani ba ne. "Trazhenta", sake dubawa wanda ke da matukar ƙarfin hali, ya ƙunshi wani abu na musamman da ke aiki wanda yake matuƙar tasiri. Babu karamin mahimmanci shine gaskiyar cewa maganin yana kunshe a cikin jerin magungunan da aka tsallake a cikin magunguna don magunguna kyauta.

Trazhenta - tsari da sashi

Masu kera, BOEHRINGER INGELHEIM PHARMA (Jamus) da BOEHRINGER INGELHEIM ROXANE (Amurka), suna sakin magungunan a cikin nau'ikan allunan zagaye masu launin ja. A gefe ɗaya alama ce da ke zana hoto na kamfanin masana'antar da ke kare miyagun ƙwayoyi daga fakes, a ɗayan - alamar "D5".

Kowannensu ya ƙunshi 5 MG na linagliptin mai aiki mai aiki da filler daban-daban kamar sitaci, fenti, hypromellose, magnesium stearate, copovidone, macrogol.

Kowane gilashi mai rufe fuska yana sanya alluna 7 ko 10 na miyagun ƙwayoyi Trazhenta, hoto wanda za'a iya gani a wannan sashin. A cikin akwatin suna iya zama lamba daban - daga faranti biyu zuwa takwas. Idan ƙuƙwalwar ta ƙunshi sel 10 tare da allunan, to a cikin akwatin za a sami irin waɗannan faranti 3.

Pharmacology

Zai yiwu a sami nasarar maganin ne saboda hanawar ayyukan dipeptidyl peptidase (DPP-4). Wannan enzyme yana da lalacewa

a kan kwayoyin HIP da GLP-1, waɗanda ke taka muhimmiyar rawa wajen kiyaye daidaituwar glucose. Yankunan sun haɓaka haɓakar insulin, taimakawa sarrafa glycemia, da hana ɓoyewar glucagon. Ayyukansu na ɗan gajeren lokaci ne; daga baya, HIP da GLP-1 suna lalata enzymes. Trazhenta yana da alaƙa da DPP-4, wannan yana ba ku damar kula da lafiyar abubuwan da suka faru har ma da ƙara yawan ƙarfin su.

Hanyar tasiri na Trazhenty yana kama da ka'idodin aikin wasu analogues - Januvius, Galvus, Ongliza. Ana samar da HIP da GLP-1 lokacin da abubuwan gina jiki suka shiga jiki. Tasirin magungunan ba shi da alaƙa da haɓakar haɓakar ƙwayoyinsu, magani kawai yana ƙara tsawon lokacin bayyanar su. Sakamakon irin waɗannan halayen, Trazhenta, kamar sauran incretinomimetics, ba ya tayar da haɓakar ƙwaƙwalwar ƙwayar cuta, kuma wannan babbar fa'ida ce akan sauran azuzuwan magungunan cututtukan jini.

Idan matakin sukari bai wuce yin tasiri sosai ba, incretins suna taimakawa wajen haɓaka samarwar insulin da ke cikin sel-cells-sel. Hormone GLP-1, wanda ke da mafi mahimmancin jerin abubuwan yiwuwar idan aka kwatanta da GUI, yana toshe tsarin haɗin glucagon a cikin ƙwayoyin hanta. Duk waɗannan hanyoyin suna taimakawa sosai ta kula da yawan ƙwayar cuta a matakin da ya dace - don rage glycosylated haemoglobin, yawan sukari da azumi da kuma motsa jiki bayan motsa jiki tare da tsawan sa'a biyu. A cikin ƙwaƙwalwar ƙwayar cuta tare da shirye-shiryen metformin da sulfonylurea, sigogi na glycemic suna haɓaka ba tare da samun nauyi mai mahimmanci ba.

Pharmacokinetics

Bayan an shiga cikin narkewa, ana shan maganin da sauri, ana lura da Cmax bayan awa daya da rabi. Taro yana raguwa a matakai biyu.

Yin amfani da Allunan tare da abinci ko daban a kan pharmacokinetics na miyagun ƙwayoyi ba su tasiri ba. A bioavailability na miyagun ƙwayoyi ya kai 30%. Relativelyan ƙaramin isan kashi yana cikin metabolized, 5% kodan ya raba shi, kashi 85% kuma an rage shi da feces. Duk wani ilimin cutar kodan baya buƙatar cire magani ko canje-canje na kashi. Ba a yi nazarin fasalin magungunan likitanci a cikin yara ba.

Wanene magani ga

An wajabta Trazent azaman magani na farko ko a hade tare da sauran magunguna masu rage sukari.

1. Monotherapy. Idan mai ciwon sukari bai yarda da kwayoyi na manyan bigins ba kamar metformin (alal misali, tare da cututtukan koda ko rashin jituwa ga abubuwanda ya kunsa), kuma gyaran rayuwa baya kawo sakamakon da ake so.
2. Wajan bangarori biyu. An tsara Trazent tare da shirye-shiryen sulfonylurea, metformin, thiazolidinediones. Idan mai haƙuri yana kan insulin, incretinomimetic na iya haɓaka shi.
3. Zaɓin ɓangarori uku. Idan magunguna na baya da suka gabata basu da inganci sosai, an haɗa Trazhenta tare da insulin da wasu nau'ikan maganin antidiabetic tare da wani tsarin aikin daban.

Wanda ba a sanya wa Trazhent ba

An ba da maganin Linagliptin don irin waɗannan nau'ikan masu ciwon sukari:

• Type 1 ciwon sukari
• Ketoacidosis tsokani da ciwon sukari,
• Ciki da lactating
• Yara da matasa
• Hypersensitivity ga abubuwan da ke cikin tsari.

Sakamakon mara amfani

A bayan shan linagliptin, sakamako masu illa na iya haɓaka:

• Nasopharyngitis (cuta mai kamuwa da cuta)
• Cutar motsa jiki
• Rashin hankali
• Ciwan huhu
• Anaruwar triglycerol (lokacin da aka haɗu da magungunan aji na sulfonylurea),
• Valuesara darajar LDL (tare da gudanar da lokaci guda na pioglitazone),
• Girman jiki
• Alamar cutar hypoglycemic (a bango na tushen kashi biyu- da uku).

Mitar da adadin raunin da ke haifar bayan cinye Trazhenta daidai yake da adadin haɗarin da ke faruwa bayan amfani da placebo. Mafi sau da yawa, sakamako masu illa suna faruwa tare da rikice-rikice na lamuran Trazhenta tare da abubuwan da suka dace da metformin da kuma abubuwan da suka samo asali na sulfonylurea.

Magungunan zai iya haifar da rikice-rikice na daidaituwa, yana da mahimmanci a yi la'akari da wannan lokacin tuki motocin da keɓaɓɓun hanyoyin.

Yawan abin sama da ya kamata

An ba wa mahalarta allunan 120 (600 MG) a lokaci guda. Doaya daga cikin adadin da aka samu bai shafi lafiyar masu sa kai daga ƙungiyar kula da lafiya ba. A cikin masu ciwon sukari, yawan masu fama da cutar yawan jini ba a yin rikodin su. Amma duk da haka, idan akwai haɗari ko ganganci na amfani da allurai da yawa a lokaci guda, wanda aka azabtar dole ne kurkura ciki da hanji don cire sashin da ba a kwance ba na maganin, ba da sihiri da sauran magunguna daidai da alamun, nuna likita.

Yadda ake shan magani

A daidai da umarnin don amfani, ya kamata a karɓi trazent 1 kwamfutar hannu (5 MG) sau uku a rana. Idan ana amfani da maganin a cikin hadaddun magani a layi daya tare da metformin, to ana kiyaye sashi na ƙarshen.

Masu fama da cutar siga tare da na koda ko hepatic kasawa basa buƙatar daidaita sashi. Nora'idojin ba su banbanta ga marasa lafiya na tsufa. A cikin tsufa (daga shekaru 80) tsufa, ba a ba da izinin Trazhenta saboda ƙarancin ƙwarewar asibiti a wannan rukunin shekarun.

Idan lokacin shan magani ya baci, yakamata ku sha kwaya da wuri-wuri. Ba shi yiwuwa a ninka na yau da kullun. Amfani da maganin bai dace da lokacin cin abinci ba.

Tasirin trazhenti akan ciki da lactation

Ba a buga sakamakon amfani da miyagun ƙwayoyi ta mata masu juna biyu ba. Ya zuwa yanzu, an gudanar da binciken ne kawai akan dabbobi, kuma babu alamun cututtukan haihuwa da ke rubuce. Kuma duk da haka, yayin daukar ciki, ba a sanya mata magunguna ba.

A cikin gwaje-gwajen da dabbobi, an gano cewa maganin yana iya shiga cikin madarar mahaifiyar mace. Don haka, a lokacin ciyarwa, ba a sanya mata Trazhent ba. Idan yanayin kiwon lafiya yana buƙatar irin wannan ilimin, an tura yaro zuwa abinci mai wucin gadi.

Ba a gudanar da gwaje-gwajen game da tasirin kwayoyi ba game da ikon yin juna biyu ba. Irin wannan gwajin da aka yi akan dabbobi bai bayyana wani hatsari ba a wannan bangaren.

Hulɗa da ƙwayoyi

Amfani da lokaci guda na Trazhenta da Metformin, koda kuwa kashi ɗaya ya wuce matsayin, ba ya haifar da bambance-bambance masu yawa a cikin magungunan magungunan.

Amfani da na guda na Pioglitazone shima baya canza magungunan magungunan duka magunguna.

Cikakken jiyya tare da Glibenclamide ba shi da haɗari ga Trazhenta, don ƙarshen, Cmax yana raguwa kaɗan (ta hanyar 14%).

Wani sakamako mai kama da wannan a cikin hulɗar an nuna shi ta hanyar wasu kwayoyi na aji na sulfonylurea.

Haɗin ritonavir + linagliptin yana ƙaruwa Cmax sau 3, irin waɗannan canje-canjen ba sa buƙatar daidaita sashi.

Haɗuwa da Rifampicin suna tsokani raguwa a Cmax Trazenti. Wani bangare, ana kiyaye halayen asibiti, amma magani ba ya aiki 100%.

Ba haɗari bane a rubuta Digoxin a lokaci guda kamar lynagliptin: magungunan magunguna na magunguna biyu ba su canzawa.

Trazhent ba ya tasiri da ikon Varfavin.

Ana lura da ƙananan canje-canje tare da yin amfani da layi ɗaya na linagliptin tare da simvastatin, amma incretin mimetic baya tasiri sosai game da halaye.

Ban da tushen jiyya tare da Trazhenta, ana iya amfani da maganin hana haihuwa.

Recommendationsarin shawarwari

Ba a sanya Trazent don kamuwa da ciwon sukari na 1 ba kuma don ketoacidosis, rikicewar ciwon sukari.

Halin da ke tattare da yanayin hypoglycemic bayan magani tare da linagliptin, wanda aka yi amfani dashi azaman maganin monotherapy, ya isa zuwa yawan waɗannan lokuta tare da placebo.

Gwaje-gwaje na asibiti sun nuna cewa yawan hailar hypoglycemia lokacin amfani da Trezhenta a cikin maganin haɗin gwiwa ba a la'akari da shi, tun da yanayin mai mahimmanci ba a haifar da linagliptin ba, amma ta hanyar metformin da kwayoyi na rukunin thiazolidinedione.

Dole ne a lura da hankali lokacin da ake rubuta Trazhenta a hade tare da magungunan aji na sulfonylurea, tunda su ne suke haifar da cutar rashin ƙarfi. A babban haɗari, ya zama dole don daidaita sashi na magunguna na ƙungiyar sulfonylurea.

Linagliptin baya shafar yiwuwar haɓakar cututtukan zuciya da jijiyoyin jini.

A haɗuwa da warkewa, ana iya amfani da Trazhent ko da tare da aiki mai rauni mai rauni.

A cikin marasa lafiya na manya (fiye da shekaru 70), lura da Trezenta ya nuna kyakkyawan sakamako na HbA1c: farkon glycosylated haemoglobin ya kasance 7.8%, karshe - 7.2%.

Magungunan ba ya haifar da karuwar haɗarin zuciya. Endarshen ƙarshen nuna halin da yawan lokuta da ke faruwa na mutuwa, bugun zuciya, bugun jini, angina pectoris mara izini na buƙatar asibiti, masu ciwon sukari waɗanda suka ɗauki linagliptin ba su da yawa kuma daga baya fiye da masu sa kai a cikin ƙungiyar kulawa waɗanda suka karɓi placebo ko kwatanta kwayoyi.

A wasu halaye, yin amfani da linagliptin ya haifar da hare-hare na matsanancin ƙwayar cuta.

Idan akwai alamun (m ciwo a cikin epigastrium, dyspeptic cuta, rauni na gaba daya), ya kamata a dakatar da magungunan kuma ku nemi likitan ku.

Ba a gudanar da nazari kan tasirin Trazhenta kan ikon tuki motocin da keɓaɓɓun hanyoyin ba, amma saboda yiwuwar daidaituwa da ke tattare da rikice-rikice, ɗauki ƙwayar idan ya cancanta, tare da jan hankali da jan hanzari tare da taka tsantsan.

Analogs da farashin magani

Ga Trazhenta na miyagun ƙwayoyi, farashin ya tashi daga 1500-1800 rubles don allunan 30 tare da sashi na 5 MG. An sake bayar da magani.

Analogues na rukuni guda na DPP-4 inhibitors sun haɗa da Janavia bisa tushen synagliptin, Ongliz dangane da saxagliptin da Galvus tare da sashin aiki mai aiki vildagliptin. Wadannan magungunan sun dace da lambar Level na ATX.

Ana amfani da irin wannan sakamako ta hanyar magungunan Sitagliptin, Alogliptin, Saksagliptin, Vildagliptin.

Babu yanayi na musamman don adana Trazenti a cikin umarnin. Shekaru uku (daidai da ranar karewa), ana ajiye allunan a zazzabi a daki (har zuwa +25 digiri) a cikin wani wuri mai duhu ba tare da izinin yara ba. Ba za a iya amfani da magungunan da suka ƙare ba, dole ne a zubar dasu.

Masu ciwon sukari da likitoci game da Trazhent

Babban ingancin Trazhenty a cikin haɗuwa iri iri da aka tabbatar ta hanyar nazarin duniya da aikin likita. Endocrinologists sun fi son yin amfani da linagliptin a matsayin magani na farko-ko kuma a haɗuwa da warkewar jiyya. Tare da hali zuwa hypoglycemia (matsanancin ƙoƙari na jiki, abinci mara kyau), a maimakon magunguna na aji na sulfonylurea, an wajabta su ga Trazent, akwai sake dubawa game da takardar sayen maganin don juriya da kiba. Yawancin masu ciwon sukari suna karɓar ƙwayar a matsayin wani ɓangare na cikakken magani, don haka yana da wahala a kimanta ƙimar ta, amma gaba ɗaya, kowa yana farin ciki da sakamakon.

Masu rarrabuwa na DPP-4, wanda Trazhenta suke, ana rarrabe shi ba kawai ta hanyar ƙarfin antidiabetic ba, amma har da ƙaruwa na aminci, tunda ba su haifar da tasirin hypoglycemic ba, ba da gudummawa ga ƙimar nauyi, kuma ba sa ɓacin lalacewar renal. Zuwa yau, wannan aji na kwayoyi ana ɗauka ɗaya daga cikin manyan alƙawarin shawo kan cutar guda 2.